Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 17Triple Negative Breast Neoplasms 13Ovarian Neoplasms 2Breast Cancer Metastatic 2Uterine Cervical Neoplasms 1Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Systematic Review of the pCR Rate of Apatinib Combined With Albumin Paclitaxel and Carboplatin Regimen for Neoadjuvant Therapy of Triple-negative Breast Cancer 1Stomach Neoplasms 1Neoplasms 1HR+/HER2-breast Cancer 1HER2-negative Breast Cancer Brain Metastases 1Fludzoparib" and Anti-angiogenic 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Organoids 1Advanced Triple-Negative Breast Cancer 1Advanced Triple Negative Breast Cancer 1Advanced Breast Cancer 1

Interventions

Fulvestrant 19Letrozole 10Anastrozole 8Capecitabine 5palbociclib 4olaparib 4Paclitaxel 4Injections 4Goserelin 4Docetaxel 4trastuzumab deruxtecan 3pyrotinib 3exemestane 3Vinorelbine 3Aromatase Inhibitors 3toripalimab 2sacituzumab govitecan 2ribociclib 2eribulin 2elacestrant 2dalpiciclib 2abemaciclib 2Trastuzumab 2Gonadotropin-Releasing Hormone 2FCN-437c 2Everolimus 2Dasatinib 2Alpelisib 2Albumin-Bound Paclitaxel 2AZD9833 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Cancer × apatinib × Breast × Clear all
NCT06447623 2024-06-07

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Fudan University

Phase 3 Recruiting
184 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡